Dr. Mark Albert, M.D.
Plastic Surgery (Plastic and Reconstructive Surgery Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 119
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Plastic and Reconstructive Surgery Physician primary
MA license 244762 -
Plastic Surgery Physician
NY license 283853
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 119
- Services billed
- 449
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Preparation of skin graft site of face, scalp, eyelids, mouth, neck, ears, around eyes, genitals, hands, feet, fingers, or toes, 100.0 sq cm or 1% body area for infants and children, or less | 43 | 36 |
| Established patient office or other outpatient visit, 20-29 minutes | 26 | 25 |
| Repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet by transferring skin, 10.0 sq cm or less | 21 | 20 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | 18 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Cephalexin Other prescribers in New York, NY | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $16.03 in total to this clinician.
| Tela Bio, Inc. | $16.03 |
|---|
| Food and Beverage | $16.03 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $75,000 in research payments for these studies, mostly to the institutions running them.
- Experience Using Closed Incision Negative Pressure Dressings in Breast Reduction and Breast Lift.
Solventum Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.